Taselisib and Enzalutamide in Treating Patients With Androgen Receptor Positive Triple-Negative Metastatic Breast Cancer

Clinical trial NCT02457910 · TERMINATED

Trial details

NCT number: NCT02457910
Sponsor: Vanderbilt-Ingram Cancer Center
Status: TERMINATED
Phase: Phase 1, Phase 2
Study type: INTERVENTIONAL

Estrogen Receptor Negative Estrogen Receptor Positive HER2/Neu Negative Progesterone Receptor Negative Progesterone Receptor Positive Stage IV Breast Cancer Triple-Negative Breast Carcinoma

Start date: 2015-06-01
Primary completion: 2018-12-01
Enrollment: 30

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.